Semaglutide in 2026: Key Developments That Could Shape the U.S. Market

Semaglutide has been the drug everyone’s talking about for a few years now, but 2026 is shaping up to be its biggest year yet. Between a newly approved pill, a major compounding crackdown, and Medicare finally stepping into the weight loss conversation, the landscape looks very different than it did twelve months ago. Here’s what’s actually happening and why it matters.

The Oral Semaglutide Pill Finally Hit the Market

For years, semaglutide meant a weekly injection. That changed in January 2026, when Novo Nordisk launched its 25 mg oral version of Wegovy nationwide, following FDA approval based on the OASIS and SELECT trial programs. In the OASIS 4 trial, participants lost an average of 13.6% of their body weight at 64 weeks, compared to a much smaller drop in the placebo group

The rollout has moved fast. The Wegovy pill became the fastest GLP-1 launch in U.S. history, surpassing 2 million prescriptions within its first four months on the market, helped by availability through more than 70,000 U.S. pharmacies shortly after launch. That’s a real shift for patients who were never comfortable with self-injection or the cold-chain logistics that come with it.

The FDA Is Cracking Down on Compounded Semaglutide

This is the most consequential, and most misunderstood, shift of the year. In April 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list, the mechanism that lets outsourcing facilities compound medications at scale, after finding no clinical need to keep them on it now that FDA-approved versions are widely available.

It’s not final yet. A public comment period ran through June 29, 2026, and the FDA will weigh that input before deciding. But the agency backed the proposal with real enforcement: in March 2026, it issued more than 50 warning letters to telehealth companies and compounding pharmacies, the largest coordinated action against GLP-1 compounders in U.S. history. Some major telehealth compounders have already exited the space.

The rule targets large-scale 503B outsourcing facilities specifically. Smaller 503A pharmacies compounding for individual patients under a specific prescription wouldn’t be affected, though that pathway is far more limited than the mass compounding that’s supplied much of the market in recent years. If finalized, it would permanently close bulk compounding of these drugs, even during a future shortage.

Medicare Is Covering Weight-Loss Semaglutide for the First Time

Medicare has historically excluded weight-loss drugs from coverage, pricing out a huge share of eligible patients. That changed this summer. The Medicare GLP-1 Bridge program launched July 1, 2026, bringing Part D coverage for weight-loss semaglutide to millions of beneficiaries for the first time, with copays around $50 a month. It’s a meaningful policy shift for a population that carries a disproportionate share of obesity-related conditions and previously had the least affordable access to branded GLP-1 therapy.

Competition Is Intensifying

Semaglutide isn’t the only GLP-1 story anymore. Eli Lilly’s tirzepatide has already pulled meaningful obesity-market share from Wegovy, and April 2026 brought a new rival: orforglipron, the first oral non-peptide GLP-1, launched under the brand name Foundayo. Unlike Rybelsus, it doesn’t require fasting for absorption, which is a genuine convenience edge, though uptake has lagged the Wegovy pill so far simply because it launched later.

Novo Nordisk is also defending its position from within, having submitted CagriSema (a semaglutide-cagrilintide combination) and a next-generation amylin-GLP-1 dual agonist for FDA review. Neither is expected before 2027 or 2028.

What This Means Going Forward

Oral access is up. Medicare access is up. Compounded access is very likely headed down. And the competitive field around semaglutide is only getting more crowded. Together, these developments point to a market moving toward more regulated, FDA-approved pathways to treatment, even as it keeps expanding. The FDA’s compounding decision isn’t final, Medicare’s Bridge program is brand new, and Novo Nordisk still has pipeline drugs awaiting review, so expect this story to keep moving through the rest of 2026.

As interest in semaglutide continues to grow, so does demand for high-quality materials used in laboratory research. Researchers studying GLP-1 receptor agonists should source research compounds from suppliers that provide rigorous quality standards, transparent Certificates of Analysis (COAs), and third-party purity testing. For those looking to learn more about research-grade semaglutide, visit Omni Peptides’ Semaglutide research page. 

Sources

1. U.S. Food and Drug Administration. “FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List.” April 30, 2026.
2. AJMC. “FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss.”
3. Pharmacy Times. “FDA Moves to Permanently Close the Door on Compounded GLP-1s.”
4. Heally. “Semaglutide in 2026: Usage Statistics, Top Brands, and Market Trends.”